K Thomas Robbins1, Kerwin Shannon, Francisco Vieira. 1. Division of Otolaryngology-Head and Neck Surgery, Southern Illinois University School of Medicine, Springfield, IL 62794-9677, USA. trobbins@siumed.edu
Abstract
OBJECTIVE: To determine whether superselective neck dissection (removal of 2 or less contiguous neck levels) is effective salvage surgery for patients with residual single-level adenopathy after concomitant intra-arterial cisplatin and radiotherapy. DESIGN: Analysis of prospectively collected data. SUBJECTS: The study group comprised 177 patients (239 heminecks) with N+ disease. INTERVENTIONS: Intra-arterial treatment with cisplatin (150 mg/m2) on days 1, 8, 15, and 22 and radiation therapy (2 Gy/d) 5 times per week for 7 weeks. Comparisons were made between neck-level-specific disease at restaging and pathologic disease after neck dissection. RESULTS: Tumor sites included oropharynx (n = 81), hypopharynx (39), larynx (n=27), oral cavity (n = 19), and other (n = 11). Response of nodal disease based on clinical evaluation was as follows: complete response, 89 patients (50%); partial response, 81 patients (46%); progressive disease, 4 patients (2%); and unevaluable, 3 patients (2%). Of the 89 patients whose necks were restaged as a partial response, 73 had clinical evidence of residual adenopathy involving only 1 neck level. Within this subset, 54 patients (57 heminecks) subsequently underwent a salvage neck dissection, for which comparisons were made between the restaging evidence of residual adenopathy and the pathologic findings that were specific for each neck level. Only 2 of the 54 patients had evidence of pathologic disease extending beyond the single neck level: one had disease in a contiguous neck level, and the other had disease in a noncontiguous level. The use of superselective neck dissection with removal of only 2 contiguous neck levels would have encompassed known disease in all but 1 patient. CONCLUSION: Superselective neck dissection is feasible after this specific chemoradiation protocol has been administered to patients with persistent nodal disease that is confined to 1 level.
OBJECTIVE: To determine whether superselective neck dissection (removal of 2 or less contiguous neck levels) is effective salvage surgery for patients with residual single-level adenopathy after concomitant intra-arterial cisplatin and radiotherapy. DESIGN: Analysis of prospectively collected data. SUBJECTS: The study group comprised 177 patients (239 heminecks) with N+ disease. INTERVENTIONS: Intra-arterial treatment with cisplatin (150 mg/m2) on days 1, 8, 15, and 22 and radiation therapy (2 Gy/d) 5 times per week for 7 weeks. Comparisons were made between neck-level-specific disease at restaging and pathologic disease after neck dissection. RESULTS: Tumor sites included oropharynx (n = 81), hypopharynx (39), larynx (n=27), oral cavity (n = 19), and other (n = 11). Response of nodal disease based on clinical evaluation was as follows: complete response, 89 patients (50%); partial response, 81 patients (46%); progressive disease, 4 patients (2%); and unevaluable, 3 patients (2%). Of the 89 patients whose necks were restaged as a partial response, 73 had clinical evidence of residual adenopathy involving only 1 neck level. Within this subset, 54 patients (57 heminecks) subsequently underwent a salvage neck dissection, for which comparisons were made between the restaging evidence of residual adenopathy and the pathologic findings that were specific for each neck level. Only 2 of the 54 patients had evidence of pathologic disease extending beyond the single neck level: one had disease in a contiguous neck level, and the other had disease in a noncontiguous level. The use of superselective neck dissection with removal of only 2 contiguous neck levels would have encompassed known disease in all but 1 patient. CONCLUSION: Superselective neck dissection is feasible after this specific chemoradiation protocol has been administered to patients with persistent nodal disease that is confined to 1 level.
Authors: Marc Hamoir; Carl E Silver; Sandra Schmitz; Robert P Takes; Alessandra Rinaldo; Juan P Rodrigo; K Thomas Robbins; Karen T Pitman; Jesus E Medina; Alfio Ferlito Journal: Eur Arch Otorhinolaryngol Date: 2012-10-30 Impact factor: 2.503
Authors: Carlos Suárez; Juan P Rodrigo; K Thomas Robbins; Vinidh Paleri; Carl E Silver; Alessandra Rinaldo; Jesus E Medina; Marc Hamoir; Alvaro Sanabria; Vanni Mondin; Robert P Takes; Alfio Ferlito Journal: Eur Arch Otorhinolaryngol Date: 2013-01-16 Impact factor: 2.503
Authors: Ian Ganly; Jennifer Bocker; Diane L Carlson; Salvatore D'Arpa; Maria Coleman; Nancy Lee; David G Pfister; Jatin P Shah; Snehal G Patel Journal: Head Neck Date: 2010-11-04 Impact factor: 3.147
Authors: Alfredo Páez-Carpio; Santiago Medrano-Martorell; Joan Berenguer; Africa Muxí; Isabel Vilaseca; Izaskun Valduvieco; Paola Castillo; Neus Baste; F Xavier Avilés-Jurado; Juan José Grau; Laura Oleaga Journal: Eur Arch Otorhinolaryngol Date: 2022-10-01 Impact factor: 3.236
Authors: H Hakan Coskun; Jesus E Medina; K Thomas Robbins; Carl E Silver; Primož Strojan; Afshin Teymoortash; Phillip K Pellitteri; Juan P Rodrigo; Sandro J Stoeckli; Ashok R Shaha; Carlos Suárez; Dana M Hartl; Remco de Bree; Robert P Takes; Marc Hamoir; Karen T Pitman; Alessandra Rinaldo; Alfio Ferlito Journal: Head Neck Date: 2014-06-30 Impact factor: 3.147
Authors: Giulia Bertino; Antonio Occhini; Carlo Emilio Falco; Camillo Porta; Franco Corbella; Sara Colombo; Vittoria Balcet; Patrizia Morbini; Federico Zappoli; Andrea Azzaretti; Giuseppe Rodolico; Carmine Tinelli; Marco Benazzo Journal: BMC Cancer Date: 2009-09-04 Impact factor: 4.430